(Dana-Farber Cancer Institute) A combination of two drugs -- one of them an immunotherapy agent -- could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
from EurekAlert! - Technology, Engineering and Computer Science http://bit.ly/2BPcJQ3
Sunday, February 17, 2019
Drug combination may become new standard treatment for advanced kidney cancer
About Admin -
Author Description here.. Nulla sagittis convallis. Curabitur consequat. Quisque metus enim, venenatis fermentum, mollis in, porta et, nibh. Duis vulputate elit in elit. Mauris dictum libero id justo.